2024 State of Lung Cancer: The Hopes and Hurdles of Precision Oncology with Dr. Jacob Sands
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
2024 State of Lung Cancer: The Hopes and Hurdles of Precision Oncology with Dr. Jacob Sands
-
Narrated by:
-
By:
About this listen
The novel immunotherapy drugs, though proven to be safe and effective with significant improvements in response and survival rates, have challenges as well—this episode covers the gamut.
Episode Highlights
0:00 Start
1:00 Topic of discussion
2:42 Introducing Jacob Sands, MD
3:39 NCCN guidelines for lung cancer
6:51 Recently-approved drugs for lung cancer
13:46 Patient responses to targeted mutations
17:58 Off-target side effects with drugs
21:34 State of Lung Cancer report
23:04 Estimated number of candidates for targeted therapies
26:13 Insurance coverage for biomarker testing
28:12 Other issues with ordering biomarkers
31:20 Closing comments
32:36 Outro
Want more Lungcast? Visit us at HCPLive.com/podcasts/lungcast or www.lung.org/professional-education/lungcast
What listeners say about 2024 State of Lung Cancer: The Hopes and Hurdles of Precision Oncology with Dr. Jacob Sands
Average Customer RatingsReviews - Please select the tabs below to change the source of reviews.
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.